United Therapeutics (NASDAQ:UTHR) CEO Sells $5,108,530.00 in Stock

Posted by Geri Gentry on Jun 27th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $537.74, for a total value of $5,108,530.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,785,460.62. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Trading Down 0.1%

Shares of United Therapeutics stock opened at $542.66 on Friday. The firm has a market capitalization of $23.04 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.79 and a beta of 0.57. The business has a fifty day simple moving average of $561.23 and a two-hundred day simple moving average of $525.58. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.63 earnings per share. Analysts predict that United Therapeutics Corporation will post 26.49 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Torren Management LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the 4th quarter worth about $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Check Out Our Latest Research Report on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.